3 new drugs to be included in the priority review!

On January 8, according to the latest announcement on the website of the Drug Review Center of the State Drug Administration of China, three innovative drugs were included in the list of priority reviews to be made.
Supi Medicine's new rare disease drug Nitesinon capsules, the proposed development of adaptive disorders are: combined with tyrosine and phenylalanine dietary restrictions, for the treatment of adult and pediatric patients (at any age) hereditary HT-1.
Henri Pharmaceuticals' PARP inhibitor fluorine palli capsules, the application is adapted to: for platinum-sensitive relapsed epithelyl ovarian cancer, fallopian tube cancer or primary peritoneal cancer after platinum-containing chemotherapy has reached full or partial remission.
Ideas Conry Pharmaceuticals (Sichuan Ideas Di Pharmaceuticals) and Corning Jerry jointly declared subdermal injection of PD-L1 antibody Nwoli monoantigen injection, this time to be included in the priority review of the adaptation is: previously received fluorouracil, oxaliplatin and The microsatellite highly unstable (MSI-H) advanced colorectal cancer treated by Ilithelicon and the late solid tumor of MSI-H advanced gastric cancer and other DNA mismatch repair functional defects (dMMR) that have failed at least the first-line standard treatment in the past.